NeuroOne Medical Technologies Corporation
NMTCNeuroOne Medical Technologies Corporation in brief
NeuroOne Medical Technologies Corporation is a listed company in the Medical Devices industry, based in Eden Prairie, Minnesota, USA. Its market value was $8 M on 30 October 2026, which makes it the 26,176th largest listed company in the world and the 4,334th largest in the USA on this site. In the year to September 2025 it had sales of $9 M and a net loss of $4 M. It employs about 18 people and David A. Rosa is its chief executive. Its largest product and service lines by sales in 2025 were OneRF Ablation System Revenue (100%). Its shares trade under the symbol NMTC (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About NeuroOne Medical Technologies Corporation
We are a medical technology company focused on (i) diagnostic, ablation and deep brain stimulation technology for brain related conditions such as epilepsy and Parkinson’s disease; (ii) ablation and stimulation for pain management throughout the body; and (iii) drug delivery including diagnostic and stimulation capabilities.
We have received 510(k) clearance for four of our devices from the Food and Drug Administration, including: (i) our Evo cortical electrode technology for temporary (less than 30 days) recording, monitoring, and stimulation on the surface of the brain, (ii) our Evo sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain, (iii) our OneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures, and (iv) our OneRF TN ablation system for use in procedures to create radiofrequency lesions for the treatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures. We have a distribution agreement with Zimmer, Inc. providing Zimmer Biomet Holdings, Inc. with a license to commercialize and distribute the Evo Cortical, Evo sEEG, and OneRF Brain Ablation System in the brain. We initiated a limited market release of the OneRF TN Ablation System in December 2025. The Company’s other products and indications are still under development.
From the company's annual report filed with the US SEC: read the report
NeuroOne Medical Technologies Corporation timeline
- 2010
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- ✎Renamed NEUROONE MEDICAL TECHNOLOGIES CorpFormerly Original Source Entertainment, Inc..
- 2025
- 💰Record revenue of $9 millionFY2025, the highest of the 5 years on record.
Events of NeuroOne Medical Technologies Corporation from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #4,290 (Jan 2020) · #4,207 (Jan 2021) · #5,158 (Jan 2022) · #5,174 (Dec 2022) · #5,223 (Jul 2023) · #4,179 (Jan 2024) · #2,167 (Mar 2026) · #3,968 (Aug 2026) · #4,265 (Oct 2026) · #4,337 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- n/m (loss)
- Price / sales (TTM)
- 0.9×
- Price / book
- 1.2×
- Free cash flow yield
- -34.6%
- Net margin (TTM)
- -78.9%
- Operating margin
- -46.5%
- Return on equity
- -105.5%
- Liabilities / assets
- 34.4%
- Revenue growth
- +163.8%
- R&D / revenue
- 54.7%
- Revenue per employee
- $506 K
- Profit per employee
- $-201 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $9M | +163.8% | $-4M | $-4M | -39.7% |
| Sep 2024 | $3M | +76.9% | $-12M | $-12M | -357.1% |
| Sep 2023 | $2M | +1047.1% | $-12M | $-12M | -608.2% |
| Sep 2022 | $0M | -5.6% | $-10M | $-10M | -5882.4% |
| Sep 2021 | $0M | — | $-10M | $-10M | -5527.8% |
| Sep 2020 | — | — | $-5M | $-14M | — |
| Sep 2019 | — | — | $-6M | $-7M | — |
| Dec 2016 | — | — | $-0M | $-0M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Sep 2025 | $-3M | $0M | $-3M | $-0.09 | — |
| Sep 2024 | $-11M | $0M | $-11M | $-0.46 | — |
| Sep 2023 | $-13M | $0M | $-13M | $-0.65 | — |
| Sep 2022 | $-8M | $0M | $-8M | $-0.63 | — |
| Sep 2021 | $-9M | $0M | $-9M | $-0.93 | — |
| Sep 2020 | $-3M | $0M | $-4M | $-2.52 | — |
| Sep 2019 | $-5M | $0M | $-5M | $-0.57 | — |
| Dec 2016 | $-0M | — | — | $-0.01 | — |
Quarterly results
Latest quarter to Jun 2026: revenue $2M (+15.9% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 5, 20268-KCurrent reportResults of operations · Other events
- Aug 27, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jun 12, 20268-KCurrent reportOther events
- Jun 12, 202610-Q/AQuarterly report (amended) · period to Mar 2026
- May 22, 20268-KCurrent reportRestatement · Regulation FD disclosure
- May 12, 202610-QQuarterly report · period to Mar 2026
- May 12, 20268-KCurrent reportResults of operations
- May 4, 20268-KCurrent reportOther events
- Apr 30, 20268-KCurrent reportDirectors or officers changed
- Apr 14, 20268-KCurrent reportBylaws amended
Official filings of NeuroOne Medical Technologies Corporation with the US Securities and Exchange Commission.
Annual results
- Revenue
- $9 M
- Operating income
- $-4 M
- Net income
- $-4 M
For year ending September-2025 · source: SEC filing
Balance sheet
- Total assets
- $11 M
- Total liabilities
- $4 M
- Total equity
- $7 M
As of September-2025
Top 22 institutional investors in NeuroOne Medical Technologies Corporation#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Bleichroeder LP | 666,666 | 0 (0.00%) | 7.66% | $1 M | Nov 13, 2026 |
| 2 | Vanguard Capital Management LLC | 352,150 | -624 (-0.18%) | 4.05% | $0 M | Nov 13, 2026 |
| 3 | Perkins Capital Management Inc | 159,854 | -84,802 (-34.66%) | 1.84% | $0 M | Nov 2, 2026 |
| 4 | Geode Capital Management, LLC | 93,555 | 0 (0.00%) | 1.07% | $0 M | Nov 6, 2026 |
| 5 | Sio Capital Management, LLC | 82,767 | 0 (0.00%) | 0.95% | $0 M | Nov 16, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 49,018 | 0 (0.00%) | 0.56% | $0 M | Nov 13, 2026 |
| 7 | State Street Corp | 43,015 | New | 0.49% | $0 M | Nov 12, 2026 |
| 8 | Cambridge Investment Research Advisors, Inc. | 28,715 | -28,283 (-49.62%) | 0.33% | $0 M | Nov 2, 2026 |
| 9 | BlackRock, Inc. | 24,029 | -1,092 (-4.35%) | 0.28% | $0 M | Nov 13, 2026 |
| 10 | Northern Trust Corp | 21,398 | 0 (0.00%) | 0.25% | $0 M | Nov 16, 2026 |
| 11 | Two Sigma Securities, LLC | 19,881 | New | 0.23% | $0 M | Nov 16, 2026 |
| 12 | Barclays PLC | 18,757 | +18,681 (+24580.26%) | 0.22% | $0 M | Nov 6, 2026 |
| 13 | UBS Group AG | 14,264 | +11,641 (+443.80%) | 0.16% | $0 M | Nov 10, 2026 |
| 14 | Belpointe Asset Management LLC | 12,500 | 0 (0.00%) | 0.14% | $0 M | Nov 9, 2026 |
| 15 | Morgan Stanley | 1,835 | -223 (-10.84%) | 0.02% | $0 M | Nov 13, 2026 |
| 16 | Tower Research Capital LLC (TRC) | 1,283 | +1,171 (+1045.54%) | 0.01% | $0 M | Nov 16, 2026 |
| 17 | GK Wealth Management LLC | 692 | New | 0.01% | $0 M | Oct 9, 2026 |
| 18 | Royal Bank Of Canada | 312 | New | 0.00% | $0 M | Nov 16, 2026 |
| 19 | Wells Fargo & Company/mn | 166 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 20 | Jpmorgan Chase & Co | 88 | New | 0.00% | $0 M | Nov 12, 2026 |
| 21 | Osaic Holdings, Inc. | 58 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 22 | SBI Securities Co., Ltd. | 13 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
Mutual funds holding NeuroOne Medical Technologies Corporation#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 254,938 | $1 M | 2.9% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 90,120 | $0 M | 1.0% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 49,310 | $0 M | 0.57% | <0.01% | new | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 23,642 | $0 M | 0.27% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 13,914 | $0 M | 0.16% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 11,879 | $0 M | 0.14% | <0.01% | new | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 7,716 | $0 M | 0.09% | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 4,972 | $0 M | 0.06% | <0.01% | new | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 1,479 | $0 M | 0.02% | <0.01% | new | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 9 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at NeuroOne Medical Technologies Corporation#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David J. WambekeChief Business Officer | Buy | +33,333 | $2.010 | $67 K | 199,999 | Form 4 |
| filed | Mark ChristiansonMarket Development Director | Sell | -10,000 | $3.180 | $32 K | 20,692 | Form 4 |
| filed | Edward AndrleDirector | Grant or award | +41,929 | — | — | 133,932 | Form 4 |
| filed | Jeffrey S. MathiesenDirector | Grant or award | +41,929 | — | — | 156,343 | Form 4 |
| filed | Jason Richard MillsDirector | Grant or award | +41,929 | — | — | 49,687 | Form 4 |
| filed | Paul BuckmanDirector | Grant or award | +41,929 | — | — | 178,733 | Form 4 |
| filed | David A. RosaCEO and President, Director | Shares withheld for tax | -2,458 | $0.780 | $2 K | 1.08 M | Form 4 |
| filed | Steve MertensChief Technology Officer | Shares withheld for tax | -906 | $0.780 | $707 | 152,141 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: NeuroOne Medical Technologies Corporation#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-08-27 13:34 UTC, code LUDP, resumed 13:44 UTC
- 2026-04-15 23:50 UTC, code T3, resumed 13:00 UTC
Fails to deliver
- : 817 shares at $0.97
- : 1,089 shares at $0.86
- : 1,189 shares at $0.85
- : 1,089 shares at $0.80
- : 412 shares at $0.92
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
NeuroOne Medical Technologies Corporation scorecard#
Passes 8 of the 19 checks that could be worked out: strongest in growth (4 of 5), weakest in profitability (1 of 5). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation2 of 5
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✓Price to book below its peers' median1.2×Price to book 1.2× against Medical Devices's median of 2.5×.
- ✓Price to sales below its peers' median0.9×Price to sales 0.9× against Medical Devices's median of 2.4×.
- ✗Free cash flow yield above 5%-34.6%Free cash flow is -34.6% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth4 of 5
- ✓Revenue grew in the newest year163.8%Revenue up 163.8% in fiscal 2025.
- ✓Revenue up more than 5% a year over three years276.9%276.9% a year over the three years to fiscal 2025.
- ✓Faster growth over three years than its peers' median276.9%276.9% a year against Medical Devices's median of 10.8% (73 companies).
- ✗Earnings per share grew in the newest year-0.09 vs -0.46Diluted EPS -0.09 in fiscal 2025 against -0.46 the year before (report's currency).
- ✓Net income higher than five years earlier-$4 M-$4 M in fiscal 2025 against -$14 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability1 of 5
- ✗Profitable in the newest year-$4 MNet income -$4 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-46.5%-46.5% against Medical Devices's median of -8.2% (86 companies).
- ✗Return on equity above 15%-91.5%-91.5% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-46.5%-46.5% in fiscal 2025 against -5900.0% in 2022.
Financial health1 of 3
- ✓Short-term assets cover short-term liabilities4.5×Current ratio 4.45 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-8.40Z-score -8.40 (distress zone) for fiscal 2025.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year50.0%Diluted shares up 50.0% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Medical Devices, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from NeuroOne Medical Technologies Corporation's statements, beside the median of Medical Devices.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -46.5% | -8.2% | |
| Net margin | -39.7% | -10.4% | |
| Return on equity | -91.5% | -16.8% | |
| Revenue growth, 3 years a year | 276.9% | 10.8% | |
| Revenue growth | 163.8% | 10.4% | |
| Free cash flow margin | -32.1% | -1.9% |
6of 8on the Piotroski tests of financial strength
- Net loss of $4 million, the 7th loss-making year in a row.
- Free cash flow was negative: -$3 million.
- The share count rose 50.0% in the year.
- Receivables grew 600% while revenue grew 164%: customers are paying later, or sales were booked ahead of cash.
NeuroOne Medical Technologies Corporation: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Sep 30, 2025 | FY 2024to Sep 30, 2024 | FY 2023to Sep 30, 2023 | FY 2022to Sep 30, 2022 | FY 2021to Sep 30, 2021 | FY 2020to Sep 30, 2020 | FY 2019to Sep 30, 2019 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 | FY 2015to Dec 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 9,098+163%100% | 3,453+76.9%100% | 1,952+1041%100% | 171−3.9%100% | 178—100% | — | — | — | 0—— | 0r0.7—— | |
| Cost of revenue | 3,956+66.7%43.5% | 2,373+58.7%68.7% | 1,496+518%76.6% | 242−12.3%141% | 276—155% | — | — | — | — | — | |
| Gross profit | 5,141+376%56.5% | 1,080+137%31.3% | 457—23.4% | −71—−41.4% | −98—−54.9% | — | — | — | — | — | |
| Research and development | 4,983−1.6%54.8% | 5,065−27.0%147% | 6,941+40.8%355% | 4,929+25.6%2880% | 3,925+89.1%2203% | 2,076+35.7%— | 1,529—— | — | — | — | |
| Selling, general and administrative | 7,385−6.5%81.2% | 7,902+14.1%229% | 6,926−0.8%355% | 6,979+11.5%4078% | 6,260—3514% | — | — | — | — | — | |
| Selling and marketing | 0.7−99.9%0.0% | 619—17.9% | — | — | — | — | — | — | — | — | |
| General and administrative | 5,848−10.0%64.3% | 6,498—188% | — | — | 6,260+31.7%3514% | 4,753+10.9%— | 4,284—— | — | 33+5.5%— | 31r50—— | |
| Operating expenses | 12,368−4.6%136% | 12,967−6.5%376% | 13,867+16.4%710% | 11,909+16.9%6957% | 10,185+49.2%5717% | 6,829+17.5%— | 5,813—— | — | 33+5.5%— | 31r50—— | |
| Operating income | −4,226—−46.5% | −11,887—−344% | −11,955—−612% | −10,031—−5860% | −10,218—−5736% | −4,902—— | −5,813—— | — | −33—— | −31r−49—— | |
| Interest expense and finance costs | — | — | — | — | 3.1—1.7% | — | — | 35—— | — | 14—— | |
| Net interest income | — | — | — | — | −3.1—−1.7% | −7,525—— | −285—— | — | — | — | |
| Other non-operating income (expense) | — | 125+30.7%3.6% | 96+207%4.9% | 31—18.2% | — | — | — | — | — | — | |
| Income before tax | −3,605—−39.6% | −12,318—−357% | −11,859—−607% | −10,000—−5842% | — | −2,018—— | — | — | −33—— | −31r−63—— | |
| Income tax | — | — | — | — | −271—−152% | — | — | — | 0—— | 0—— | |
| Income from continuing operations | — | — | — | — | — | — | — | — | −33—— | −31—— | |
| Income from discontinued operations | — | — | — | — | — | — | — | — | −16—— | −17—— | |
| Net income including minority interests | — | — | — | — | −9,948—−5584% | −13,640—— | −6,781—— | — | — | — | |
| Net income attributable to shareholders | −3,605—−39.6% | −12,318—−357% | −11,859—−607% | −10,000—−5842% | −9,948—−5584% | −13,640—— | −6,781—— | — | −48—— | −63—— | |
| Earnings per share, basic | -0.09—— | -0.46—— | -0.65—— | -0.63—— | -0.93—— | -2.52r-0.84—— | -0.57—— | — | -0.01—— | -0.01—— | |
| Earnings per share, diluted | -0.09—— | -0.46—— | -0.65—— | -0.63—— | -0.93—— | -2.52r-0.84—— | -0.57—— | — | -0.01—— | -0.01—— | |
| Shares, weighted average (basic) | 40+50.0%— | 27+47.7%— | 18+13.3%— | 16+49.6%— | 11—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 40+50.0%— | 27+47.7%— | 18+13.3%— | 16+49.6%— | 11+97.5%— | 5.4r16−54.3%— | 12—— | — | 5.10.0%— | 5.1—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 6,570+350%60.9% | 1,460−72.6%27.2% | 5,322−34.8%65.7% | 8,160+18.2%63.6% | 6,901+71.0%86.9% | 4,036+1448%84.8% | 261—49.0% | 26−94.9%10.6% | 522r0—69.0% | 0r1.8—0.0% | |
| Short-term investments | — | — | — | 2,981—23.2% | — | — | — | — | — | — | |
| Receivables | 1,265+616%11.7% | 177—3.3% | — | 33−31.2%0.3% | 48—0.6% | — | — | — | — | 0—0.0% | |
| Inventory | 2,227−15.5%20.6% | 2,635+52.6%49.1% | 1,727+145%21.3% | 705+617%5.5% | 98—1.2% | — | — | — | — | — | |
| Other current assets | — | 216−17.9%4.0% | 264—3.3% | — | — | — | — | — | — | — | |
| Current assets | 10,226+121%94.8% | 4,631−36.7%86.2% | 7,313−39.9%90.3% | 12,176+67.0%95.0% | 7,292+75.5%91.9% | 4,155+1277%87.3% | 302—56.7% | 34−94.2%13.4% | 576+31241%76.1% | 1.8—100% | |
| Property, plant and equipment | 259−37.8%2.4% | 417−20.7%7.8% | 526+48.7%6.5% | 354+58.3%2.8% | 223+34.5%2.8% | 166+219%3.5% | 52—9.8% | — | — | — | |
| Right-of-use (leased) assets | 255+0.1%2.4% | 255+50.8%4.7% | 169−6.8%2.1% | 181−37.2%1.4% | 289+2.4%3.6% | 282—5.9% | — | — | — | — | |
| Other intangible assets | 45−33.2%0.4% | 67−24.9%1.3% | 90−19.9%1.1% | 112−16.6%0.9% | 134−14.3%1.7% | 157−12.5%3.3% | 179—33.6% | 216+19.6%86.6% | 181—23.9% | — | |
| Total assets | 10,786+101%100% | 5,370−33.7%100% | 8,097−36.9%100% | 12,823+61.5%100% | 7,938+66.8%100% | 4,760+794%100% | 533—100% | 250−67.0%100% | 757r4.3+41082%100% | 1.8—100% | |
| Accounts payable | 1,010−1.8%9.4% | 1,029+50.2%19.2% | 685−26.1%8.5% | 928+75.4%7.2% | 529−30.6%6.7% | 763−33.8%16.0% | 1,152—216% | — | 22+106%3.0% | 11r17—591% | |
| Current liabilities | 2,303+4.1%21.4% | 2,213+23.5%41.2% | 1,793−42.1%22.1% | 3,099+162%24.2% | 1,182−49.8%14.9% | 2,356+33.1%49.5% | 1,770—332% | 3,905+477%1562% | 677r118+713%89.5% | 83—4534% | |
| Long-term debt | — | — | 55−53.8%0.7% | 120−41.1%0.9% | 203−20.2%2.6% | 254—5.3% | — | — | — | — | |
| Lease liabilities (non-current) | 143−26.4%1.3% | 194+252%3.6% | 55−53.8%0.7% | 120−41.1%0.9% | 203−20.2%2.6% | 254—5.3% | — | — | — | — | |
| Total liabilities | 3,713−18.4%34.4% | 4,548+146%84.7% | 1,848−42.6%22.8% | 3,218+132%25.1% | 1,385−48.6%17.4% | 2,694+52.2%56.6% | 1,770—332% | 5,287+417%2115% | 1,023r118+1128%135% | 83—4534% | |
| Retained earnings | −78,610—−729% | −75,004—−1397% | −62,686—−774% | −50,827—−396% | −40,827—−514% | −30,879—−649% | −17,239—−3237% | −5,325—−2130% | −266r−228—−35.2% | −180—−9796% | |
| Shareholders' equity | 7,073+760%65.6% | 822−86.8%15.3% | 6,249−34.9%77.2% | 9,604+46.5%74.9% | 6,554+217%82.6% | 2,066—43.4% | −1,238—−232% | −5,037—−2015% | −266r−114—−35.2% | −81—−4434% | |
| Total liabilities and equity | 10,786+101%100% | 5,370−33.7%100% | 8,097−36.9%100% | 12,823+61.5%100% | 7,938+66.8%100% | 4,760+794%100% | 533—100% | 250−67.0%100% | 757r4.3+41082%100% | 1.8—100% | |
| Shares outstanding | 8.3r50−73.0%— | 31+28.8%— | 24+47.6%— | 16+35.0%— | 12+62.4%— | 7.4r22−45.2%— | 13—— | 7.9+50.8%— | 5.2r5.1+2.8%— | 5.1—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | 262+6.0%2.9% | 247+23.9%7.1% | 199+68.0%10.2% | 119+46.9%69.3% | 81+69.6%45.3% | 48+72.7%— | 28—— | — | — | — | |
| Share-based compensation | 1,265−5.9%13.9% | 1,344+21.6%38.9% | 1,105+16.7%56.6% | 947−47.2%553% | 1,793−2.3%1007% | 1,836+466%— | 324—— | 77—— | — | — | |
| Cash from operating activities | −2,837—−31.2% | −11,012—−319% | −12,887—−660% | −7,520—−4393% | −8,603—−4829% | −3,425—— | −5,396—— | — | −21—— | −30r−45—— | |
| Capital expenditure | −82—−0.9% | −120—−3.5% | −384—−19.7% | −275—−161% | −67—−37.7% | −122—— | −58—— | — | — | — | |
| Intangible assets bought | — | — | — | — | — | — | −65—— | — | — | — | |
| Cash from investing activities | −82—−0.9% | −120−105%−3.5% | 2,650—136% | −3,245—−1896% | −67—−37.7% | −122—— | −123—— | — | 0—— | 0—— | |
| Shares issued | — | 837r5,034−67.2%24.2% | 2,553—131% | — | — | — | — | — | — | — | |
| Cash from financing activities | 8,029+10.5%88.3% | 7,270−1.8%211% | 7,399−38.5%379% | 12,023+4.2%7024% | 11,535+57.5%6475% | 7,323+27.0%— | 5,767—— | — | 21−29.7%— | 30r47—— | |
| Change in cash | — | — | — | — | 2,865−24.1%1608% | 3,776—— | — | — | — | — | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-Q | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD thousands; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q3 FY2026to Jun 30, 2026 | Q2 FY2026to Mar 31, 2026 | Q1 FY2026to Dec 31, 2025 | Q4 FY2025to Sep 30, 2025 | Q3 FY2025to Jun 30, 2025 | Q2 FY2025to Mar 31, 2025 | Q1 FY2025to Dec 31, 2024 | Q4 FY2024to Sep 30, 2024 | Q3 FY2024to Jun 30, 2024 | Q2 FY2024to Mar 31, 2024 | Q1 FY2024to Dec 31, 2023 | Q4 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 9,469+42.8%100% | 1,973+16.3%100% | 1,862r2,391+34.3%100% | 2,893−11.7%100% | 2,741*+907%100% | 1,696+105%100% | 1,387+0.7%100% | 3,274+235%100% | 272*−63.3%100% | 826—100% | 1,377—100% | 978—100% | 742*—100% | |
| Cost of revenue | 4,199+46.1%44.4% | 790+1.2%40.1% | 872r1,105+41.6%46.8% | 1,325−1.7%45.8% | 1,212*+824%44.2% | 781+43.6%46.1% | 615−37.6%44.4% | 1,347+89.4%41.1% | 131*−76.1%48.2% | 544—65.9% | 987—71.7% | 711—72.8% | 548*—73.9% | |
| Gross profit | 5,269+40.4%55.6% | 1,183+29.3%59.9% | 990r1,287+28.4%53.2% | 1,568−18.6%54.2% | 1,529*+984%55.8% | 915+225%53.9% | 771+97.5%55.6% | 1,927+624%58.9% | 141*−27.2%51.8% | 282—34.1% | 390—28.3% | 266—27.2% | 194*—26.1% | |
| Research and development | 5,401+8.5%57.0% | 1,425+20.5%72.2% | 1,468−2.8%78.8% | 1,390+18.6%48.0% | 1,118*+0.4%40.8% | 1,182−1.0%69.7% | 1,511+18.6%109% | 1,172−21.0%35.8% | 1,114*−37.4%409% | 1,195—145% | 1,274—92.5% | 1,483—152% | 1,779*—240% | |
| Selling, general and administrative | 7,768+4.3%82.0% | 2,182+34.8%111% | 1,919−1.1%103% | 1,885−7.7%65.2% | 1,782*−3.4%65.0% | 1,619−13.9%95.5% | 1,940−3.1%140% | 2,043−6.0%62.4% | 1,844*+16.8%677% | 1,881—228% | 2,003—145% | 2,173—222% | 1,579*—213% | |
| Selling and marketing | — | 261+74.0%13.2% | 199+26.5%10.7% | 174−15.0%6.0% | — | 150—8.8% | 157—11.4% | 205—6.3% | — | — | — | — | — | |
| General and administrative | 5,998—63.4% | 1,693+33.9%85.8% | 1,504−5.0%80.7% | 1,454−12.1%50.3% | 1,347*—49.2% | 1,265—74.6% | 1,582—114% | 1,654—50.5% | — | — | — | — | — | |
| Operating expenses | 13,169+6.0%139% | 3,607+28.8%183% | 3,387−1.8%182% | 3,275+1.8%113% | 2,900*−2.0%106% | 2,801−8.9%165% | 3,451+5.3%249% | 3,216−12.1%98.2% | 2,958*−11.9%1086% | 3,076—372% | 3,277—238% | 3,657—374% | 3,358*—453% | |
| Operating income | −7,900—−83.4% | −2,424—−123% | −2,397r−2,101—−129% | −1,707−200%−59.0% | −1,371*—−50.0% | −1,887—−111% | −2,680—−193% | 1,711—52.3% | −2,817*—−1034% | −2,794—−338% | −2,886—−210% | −3,390—−347% | −3,165*—−427% | |
| Other non-operating income (expense) | — | — | — | — | — | — | 19−38.5%1.4% | 9.4−79.4%0.3% | 22*−25.0%8.2% | 26—3.2% | 31—2.3% | 46—4.7% | 30*—4.0% | |
| Income before tax | −7,445—−78.6% | −2,006—−102% | −2,382r−2,086—−128% | −1,438−181%−49.7% | −1,619*—−59.1% | −1,501—−88.5% | −2,271—−164% | 1,785—54.5% | −3,351*—−1231% | −2,768—−335% | −2,855—−207% | −3,345—−342% | −3,135*—−423% | |
| Net income attributable to shareholders | −7,445—−78.6% | −2,006—−102% | −2,382r−2,086—−128% | −1,438−181%−49.7% | −1,619*—−59.1% | −1,501—−88.5% | −2,271—−164% | 1,785—54.5% | −3,351*—−1231% | −2,768—−335% | −2,855—−207% | −3,345—−342% | −3,135*—−423% | |
| Earnings per share, basic | — | -0.23—— | -0.28r-0.25—— | -0.03−150%— | — | -0.19r-0.03—— | -0.44r-0.07—— | 0.06—— | — | -0.10—— | -0.11—— | -0.14—— | — | |
| Earnings per share, diluted | — | -0.28—— | -0.28r-0.25—— | -0.03−150%— | — | -0.19r-0.03—— | -0.44r-0.07—— | 0.06—— | — | -0.10—— | -0.11—— | -0.14—— | — | |
| Shares, weighted average (basic) | 8.7+6.9%— | 8.7+6.9%— | 8.5+63.6%— | 50+63.2%— | — | 8.1r49−70.4%— | 5.2r31−80.0%— | 31+28.5%— | — | 27—— | 26—— | 24—— | — | |
| Shares, weighted average (diluted) | 8.7+7.9%— | 8.7+7.9%— | 8.5+63.6%— | 50+63.0%— | — | 8.1r49−70.4%— | 5.2r31−80.0%— | 31+28.7%— | — | 27—— | 26—— | 24—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 2,048—33.1% | 2,048−74.5%33.1% | 2,804+112%37.0% | 3,562+214%41.5% | 6,570+350%60.9% | 8,040+396%74.3% | 1,320−45.8%29.6% | 1,134−57.7%17.5% | 1,460−72.6%27.2% | 1,620—33.0% | 2,435—45.1% | 2,681—46.0% | 5,322—65.7% | |
| Receivables | 1,099—17.8% | 1,099—17.8% | 1,897r2,427+495%25.1% | 2,662+12.4%31.0% | 1,265+616%11.7% | — | 319−42.6%7.2% | 2,369+336%36.5% | 177—3.3% | 411—8.4% | 556—10.3% | 543—9.3% | — | |
| Inventory | 2,290—37.0% | 2,290+20.7%37.0% | 2,099r1,867+14.4%27.7% | 1,666−13.7%19.4% | 2,227−15.5%20.6% | 1,898+5.8%17.5% | 1,835+39.9%41.2% | 1,931+20.0%29.7% | 2,635+52.6%49.1% | 1,793—36.5% | 1,312—24.3% | 1,609—27.6% | 1,727—21.3% | |
| Other current assets | — | — | — | — | — | — | — | 195+813%3.0% | 216−17.9%4.0% | 261—5.3% | 408—7.6% | 21—0.4% | 264—3.3% | |
| Current assets | 5,789—93.6% | 5,789−43.1%93.6% | 7,107r7,404+89.3%93.9% | 8,067+41.2%94.0% | 10,226+121%94.8% | 10,171+149%94.0% | 3,754−20.3%84.2% | 5,712+12.1%87.9% | 4,631−36.7%86.2% | 4,085—83.2% | 4,710—87.3% | 5,093—87.5% | 7,313—90.3% | |
| Property, plant and equipment | 202—3.3% | 202−35.7%3.3% | 231−31.1%3.0% | 245−35.8%2.9% | 259−37.8%2.4% | 315−33.4%2.9% | 335−32.5%7.5% | 382−24.4%5.9% | 417−20.7%7.8% | 472—9.6% | 496—9.2% | 505—8.7% | 526—6.5% | |
| Right-of-use (leased) assets | 167—2.7% | 167−41.2%2.7% | 197−36.9%2.6% | 226−33.3%2.6% | 255+0.1%2.4% | 284+0.6%2.6% | 312+181%7.0% | 339+142%5.2% | 255+50.8%4.7% | 282—5.7% | 111—2.1% | 140—2.4% | 169—2.1% | |
| Other intangible assets | 28—0.5% | 28−44.2%0.5% | 34−39.8%0.4% | 39−36.2%0.5% | 45−33.2%0.4% | 51−30.6%0.5% | 56−28.5%1.3% | 62−26.6%0.9% | 67−24.9%1.3% | 73—1.5% | 78—1.5% | 84—1.4% | 90—1.1% | |
| Total assets | 6,186—100% | 6,186−42.8%100% | 7,569r7,865+69.8%100% | 8,578+32.1%100% | 10,786+101%100% | 10,819+120%100% | 4,457−17.4%100% | 6,494+11.5%100% | 5,370−33.7%100% | 4,913—100% | 5,395—100% | 5,822—100% | 8,097—100% | |
| Accounts payable | 906—14.6% | 906+93.6%14.6% | 934+2.6%12.3% | 552−25.8%6.4% | 1,010−1.8%9.4% | 468−38.4%4.3% | 911+16.6%20.4% | 745−2.0%11.5% | 1,029+50.2%19.2% | 759—15.5% | 781—14.5% | 760—13.1% | 685—8.5% | |
| Current liabilities | 2,041—33.0% | 2,041+43.2%33.0% | 1,689−4.2%22.3% | 1,258−19.9%14.7% | 2,303+4.1%21.4% | 1,426−15.7%13.2% | 1,763+14.5%39.6% | 1,571+13.6%24.2% | 2,213+23.5%41.2% | 1,691—34.4% | 1,540—28.6% | 1,383—23.8% | 1,793—22.1% | |
| Long-term debt | — | — | — | — | — | — | — | — | — | — | — | — | 55—0.7% | |
| Lease liabilities (non-current) | 73—1.2% | 73−58.2%1.2% | 92−55.4%1.2% | 110−53.5%1.3% | 143−26.4%1.3% | 175−16.5%1.6% | 207—4.6% | 237+1031%3.7% | 194+252%3.6% | 210—4.3% | — | 21—0.4% | 55—0.7% | |
| Total liabilities | 2,419—39.1% | 2,419−8.5%39.1% | 2,491−25.2%32.9% | 2,176−38.9%25.4% | 3,713−18.4%34.4% | 2,642+39.0%24.4% | 3,331+116%74.7% | 3,559+153%54.8% | 4,548+146%84.7% | 1,901—38.7% | 1,540—28.6% | 1,404—24.1% | 1,848—22.8% | |
| Retained earnings | −84,436—−1365% | −84,436—−1365% | −82,430r−82,133—−1089% | −80,048—−933% | −78,610—−729% | −76,991—−712% | −75,490—−1694% | −73,219—−1127% | −75,004—−1397% | −71,654—−1459% | −68,886—−1277% | −66,031—−1134% | −62,686—−774% | |
| Shareholders' equity | 3,768—60.9% | 3,768−53.9%60.9% | 5,077r5,374+351%67.1% | 6,402+118%74.6% | 7,073+760%65.6% | 8,177+172%75.6% | 1,126−70.8%25.3% | 2,935−33.6%45.2% | 822−86.8%15.3% | 3,012—61.3% | 3,854—71.4% | 4,418—75.9% | 6,249—77.2% | |
| Total liabilities and equity | 6,186—100% | 6,186−42.8%100% | 7,569r7,865+69.8%100% | 8,578+32.1%100% | 10,786+101%100% | 10,819+120%100% | 4,457−17.4%100% | 6,494+11.5%100% | 5,370−33.7%100% | 4,913—100% | 5,395—100% | 5,822—100% | 8,097—100% | |
| Shares outstanding | 8.7—— | 8.7−82.5%— | 8.6−72.5%— | 50+63.5%— | 8.3r50−73.0%— | 50+78.9%— | 31+19.2%— | 31+24.2%— | 31+28.8%— | 28—— | 26—— | 25—— | 24—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 237−9.4%2.5% | 47*−29.4%2.4% | 60*−8.5%3.2% | 66+0.6%2.3% | 64*+0.3%2.3% | 67*+5.5%3.9% | 66*+7.8%4.7% | 65+11.0%2.0% | 64*+2.6%23.6% | 63*—7.6% | 61*—4.4% | 59—6.0% | 63*—8.4% | |
| Share-based compensation | 1,413+13.3%14.9% | 353+11.4%17.9% | 342+36.8%18.4% | 359+5.9%12.4% | 359*+5.3%13.1% | 317−6.5%18.7% | 250−29.9%18.0% | 339+9.9%10.4% | 340*+25.5%125% | 339—41.0% | 357—25.9% | 309—31.6% | 271*—36.6% | |
| Cash from operating activities | −7,052—−74.5% | −1,082*—−54.8% | −1,329*—−71.4% | −3,116−1598%−108% | −1,526*—−55.7% | −1,464*—−86.3% | −56*—−4.0% | 208—6.4% | −2,667*—−979% | −2,360*—−286% | −2,175*—−158% | −3,809—−390% | −2,903*—−391% | |
| Capital expenditure | −110—−1.2% | −20*—−1.0% | −39*—−2.1% | −41—−1.4% | −11*—−0.4% | −44*—−2.6% | −3.2*—−0.2% | −24—−0.7% | −37*—−13.6% | −15*—−1.8% | −31*—−2.3% | −37—−3.8% | −58*—−7.8% | |
| Cash from investing activities | −110—−1.2% | −20*—−1.0% | −39*—−2.1% | −41—−1.4% | −11*—−0.4% | −44*—−2.6% | −3.2*—−0.2% | −24—−0.7% | −37*—−13.6% | −15*—−1.8% | −31*—−2.3% | −37—−3.8% | −50*—−6.8% | |
| Shares issued | — | 359*−96.1%18.2% | — | — | — | 9,200*+447%542% | — | — | −4,197r0*—−1541% | 1,683—204% | 2,094—152% | 1,256—128% | 0*—0.0% | |
| Cash from financing activities | 1,169−88.9%12.4% | 345*−95.8%17.5% | 610*+149%32.7% | 148—5.1% | 67*−97.4%2.4% | 8,226*+427%485% | 245*−87.5%17.7% | −509−142%−15.6% | 2,544*−51.0%934% | 1,561*—189% | 1,960*—142% | 1,205—123% | 5,192*—700% | |
| Report | Worked out | 10-Q | 10-Q/A | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What NeuroOne Medical Technologies Corporation sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- OneRF Ablation System Revenue$9 M100%—
Source: SEC annual report (XBRL data) · as of Sep 30, 2025
Executive pay at NeuroOne Medical Technologies Corporation#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mr. Rosa | $1.2 M | $1.3 M | $606 K | $53 |
| 2024David A. Rosa | $2.0 M | $1.9 M | $655 K | $59 |
| 2023David A. Rosa | $990 K | $716 K | $424 K | $53 |
Source: SEC proxy statement (Form DEF 14A) · as of Sep 30, 2025
Events at NeuroOne Medical Technologies Corporation#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Financial statements withdrawn 1 · Directors and officers 4 · Material agreement 1 · Bylaws or fiscal year changed 1 · Shareholder vote 3 · Results announced 10
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Results announced | 8-K | |
| Financial statements withdrawn | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changed | 8-K | |
| Directors and officersShareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Directors and officersShareholder vote | 8-K/A | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 5, 2026
Acquisitions and funding#
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2021 | $13 M | Private placement after listing | $10 to $50 million | 36 | equity, options | SEC |
| Apr 2020 | $2 M | Private placement after listing | $2 to $10 million | 33 | equity, debt, options | SEC |
| Nov 2019 | $1 M | Private placement after listing | Under $2 million | 16 | equity, debt, options | SEC |
| Jul 2018 | $2 M | Private placement after listing | Under $2 million | 21 | equity, options | SEC |
| Oct 2017 | $1 M | Private placement after listing | Under $2 million | 20 | debt, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How NeuroOne Medical Technologies Corporation compares in Medical Devices
- Market cap$8 M · higher than 4% of 142
- Revenue$9 M · higher than 16% of 155
- Net margin-78.9% · higher than 19% of 144
- Revenue growth163.8% · higher than 98% of 104
- Price / sales0.9× · lower than 87% of 96
- Price / book1.2× · lower than 84% of 99
- FCF yield-34.6% · higher than 23% of 76
Peer comparison · Medical Devices
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| NeuroOne Medical Technologies Corporation🇺🇸 | $8 M | — | -78.9% | +163.8% |
| Abbott Laboratories🇺🇸 | $181.1 B | 38.5× | 9.8% | +5.7% |
| Medtronic plc🇺🇸 | $121.2 B | 23.2× | 13.9% | +8.4% |
| Stryker Corporation🇺🇸 | $116.5 B | 32.2× | 13.8% | +11.2% |
| Boston Scientific Corporation🇺🇸 | $66.2 B | 18.9× | 16.6% | +19.9% |
| Edwards Lifesciences Corporation🇺🇸 | $52.8 B | 51.7× | 15.3% | +11.6% |
| Shenzhen Mindray Bio-Medical Electronics Co., Ltd.🇨🇳 | $27.8 B | 23.6× | 24.4% | — |
| STERIS plc🇮🇪 | $20.4 B | 24.6× | 13.4% | +8.7% |
| Zimmer Biomet Holdings, Inc.🇺🇸 | $18.2 B | 23.8× | 8.9% | +7.2% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending September-2025
- Balance sheet:
- As of September-2025
- Employees:
- As of September 30, 2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at NeuroOne Medical Technologies Corporation? Verify and update this profile — free
Show NeuroOne Medical Technologies Corporation's ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.